Table 3.

Frequency of EMP3 promoter methylation according to WHO grading.

Tumor type	Patients (n)	EMP3 hypermethylation (%)
WHO grade I
Pilocytic astrocytoma	18	4 (22.2%)
WHO grade II
Diffuse and gemistocytic astrocytoma	9	3 (33.3%)
Oligodendroglioma	42	33 (78.6%)
Oligoastrocytoma	12	9 (75%)
Total	63	45 (71.4%)
WHO grade III
Anaplastic astrocytoma	8	3 (37.5%)
Anaplastic oligodendroglioma	31	13 (41.9%)
Anaplastic oligoastrocytoma	8	5 (62.5%)
Total	47	21 (44.7%)
WHO grade IV
pGBM	62	5 (8.1%)
sGBM	3	3 (100%)
Total	65	8 (12.3%)